Clinical Report: GSLS Course Explores Advanced Myopia Management Strategies
Overview
Revise to emphasize the session's focus on treatment variability and personalized approaches.
Background
Myopia is a growing global concern, with increasing prevalence among children and adolescents. Effective management strategies are crucial to slow progression and prevent associated complications. The evolving landscape of myopia treatment necessitates continuous education and adaptation of clinical practices to incorporate new evidence and technologies.
Data Highlights
No specific numerical data presented in the article.
Key Findings
- Ortho-k is effective in slowing axial length progression, but responses vary among individuals.
- The axial length-to-corneal radius ratio is a better predictor of myopia progression than axial length alone.
- Emerging treatment combinations, such as low-dose atropine with ortho-k, show promise for rapid myopia progressors.
- Understanding corneal biomechanical changes and washout periods is critical in ortho-k management.
- Individualized patient care is essential in myopia management, incorporating both clinical and lifestyle recommendations.
Clinical Implications
Detail practical steps for continuous monitoring and adaptation in myopia management.
Conclusion
The session at the GSLS underscores the need for an individualized, evidence-based approach to myopia management, highlighting the importance of staying informed about evolving treatment strategies.
References
- Contact Lens Spectrum, 2019 -- HIGHLIGHTS FROM THE 2019 GSLS
- Contact Lens Spectrum, 2023 -- MASTERING MYOPIA
- Contact Lens Spectrum, 2023 -- MASTERING MYOPIA
- Contact Lens Spectrum, 2025 -- GSLS Course Traces the Evolution of Scleral Lenses
- IMI 2025 Digest - Myopia Institute
- Atropine and Spectacle lens Combination Treatment (ASPECT), 2025 -- British Journal of Ophthalmology
- Contact Lens Spectrum — HIGHLIGHTS FROM THE 2019 GSLS
- IMI 2025 Digest - Myopia Institute
- Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine | British Journal of Ophthalmology
- Red Light Therapy for Myopia—Current Regulatory Changes in China | Ophthalmology | JAMA Ophthalmology | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.


